2.73
price up icon0.37%   0.010
 
loading
Affimed N V stock is traded at $2.73, with a volume of 83,885. It is up +0.37% in the last 24 hours and down -19.71% over the past month. Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
See More
Previous Close:
$2.72
Open:
$2.83
24h Volume:
83,885
Relative Volume:
0.89
Market Cap:
$45.32M
Revenue:
$19.91M
Net Income/Loss:
$-127.11M
P/E Ratio:
-3.5027
EPS:
-0.7794
Net Cash Flow:
$-132.44M
1W Performance:
-25.21%
1M Performance:
-19.71%
6M Performance:
-46.99%
1Y Performance:
-43.94%
1-Day Range:
Value
$2.70
$2.96
1-Week Range:
Value
$2.70
$3.76
52-Week Range:
Value
$2.70
$8.95

Affimed N V Stock (AFMD) Company Profile

Name
Name
Affimed N V
Name
Phone
-
Name
Address
-
Name
Employee
78
Name
Twitter
@affimed
Name
Next Earnings Date
2024-12-13
Name
Latest SEC Filings
Name
AFMD's Discussions on Twitter

Compare AFMD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
AFMD 2.73 45.32M 19.91M -127.11M -132.44M -0.7794
VRTX 447.42 115.74B 10.63B -479.80M -1.35B 13.33
REGN 746.52 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 590.60 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.15 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.88 24.49B 3.30B -501.07M 1.03B 11.54

Affimed N V Stock (AFMD) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-12-22 Initiated H.C. Wainwright Buy
Oct-10-22 Downgrade Stifel Buy → Hold
Aug-18-22 Resumed Wells Fargo Overweight
Mar-31-22 Initiated Piper Sandler Overweight
Feb-23-22 Initiated Cantor Fitzgerald Overweight
Oct-21-21 Initiated Truist Buy
Sep-30-21 Initiated Stifel Buy
Mar-31-21 Initiated Credit Suisse Outperform
Mar-28-19 Initiated SVB Leerink Outperform
Aug-28-18 Upgrade Jefferies Hold → Buy
Jul-14-17 Initiated SunTrust Buy
Aug-12-16 Downgrade Leerink Partners Outperform → Mkt Perform
May-19-16 Downgrade Leerink Partners Outperform → Mkt Perform
Dec-10-15 Initiated Laidlaw Buy
Dec-04-15 Initiated Wells Fargo Outperform
Sep-09-15 Initiated Jefferies Hold
Aug-06-15 Reiterated Oppenheimer Outperform
Jun-22-15 Reiterated Jefferies Buy
View All

Affimed N V Stock (AFMD) Latest News

pulisher
Nov 20, 2024

Affimed Q3 2024 Earnings Preview - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Is Affimed N.V. (AFMD) the Best German Stock to Buy Now? - Insider Monkey

Nov 19, 2024
pulisher
Nov 19, 2024

10 Best German Stocks To Buy Now - Insider Monkey

Nov 19, 2024
pulisher
Nov 19, 2024

Cantor Fitzgerald Reiterates "Overweight" Rating for Affimed (NASDAQ:AFMD) - MarketBeat

Nov 19, 2024
pulisher
Nov 15, 2024

Affimed N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 15, 2024
pulisher
Nov 15, 2024

Stifel Nicolaus Cuts Affimed (NASDAQ:AFMD) Price Target to $4.00 - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Affimed N.V. (NASDAQ:AFMD) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024
pulisher
Nov 15, 2024

Affimed's (AFMD) Buy Rating Reiterated at HC Wainwright - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Earnings call: Affimed reports promising results and strategic focus - Investing.com India

Nov 15, 2024
pulisher
Nov 15, 2024

Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating F - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges with ... - Yahoo Finance

Nov 15, 2024
pulisher
Nov 14, 2024

Affimed Reports Q3 2024 Financial Results and Updates - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Affimed N.V.: Q3 Earnings Snapshot - Houston Chronicle

Nov 14, 2024
pulisher
Nov 14, 2024

Affimed NV earnings missed by €0.09, revenue fell short of estimates - Investing.com Canada

Nov 14, 2024
pulisher
Nov 14, 2024

Affimed Faces Growing Losses Amid Financial Struggles - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Affimed Reports Third Quarter 2024 Financial Results & Business Update - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

Affimed N.V.: Q3 Earnings Snapshot | National Business News | voiceofalexandria.com - Voice Of Alexandria

Nov 14, 2024
pulisher
Nov 14, 2024

Affimed Q3 Revenue Drops 90%, but Net Loss Narrows as R&D Costs Decline | AFMD Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 13, 2024

Affimed (AFMD) Scheduled to Post Quarterly Earnings on Thursday - Defense World

Nov 13, 2024
pulisher
Nov 07, 2024

Affimed to Report Third Quarter 2024 Financial Results and Corporate Update on November 14, 2024 - Marketscreener.com

Nov 07, 2024
pulisher
Nov 07, 2024

Affimed (AFMD) Scheduled to Post Earnings on Thursday - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024 - GlobeNewswire

Nov 06, 2024
pulisher
Nov 06, 2024

Affimed (AFMD) Sets Q3 2024 Earnings Call for Nov 14: Immuno-Oncology Updates Ahead | AFMD Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 06, 2024

Affimed (NASDAQ:AFMD) Share Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Affimed Announces Acceptance of Three Abstracts at the 2024 - GlobeNewswire

Nov 06, 2024
pulisher
Nov 05, 2024

Affimed to Present Promising AML Treatment Data at ASH 2024 Annual Meeting | AFMD Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma - Yahoo Finance UK

Nov 05, 2024
pulisher
Oct 28, 2024

Affimed (NASDAQ:AFMD) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Affimed (NASDAQ:AFMD) Given Average Rating of “Buy” by Analysts - Defense World

Oct 28, 2024
pulisher
Oct 27, 2024

Affimed (NASDAQ:AFMD) Short Interest Update - MarketBeat

Oct 27, 2024
pulisher
Oct 24, 2024

683 Capital Management, LLC Expands Stake in Affimed NV - Yahoo Finance

Oct 24, 2024
pulisher
Oct 15, 2024

Affimed Appoints New Director Amid Strategic Moves - TipRanks

Oct 15, 2024
pulisher
Oct 15, 2024

Affimed N : Annual General Meeting Results Form 6 K - Marketscreener.com

Oct 15, 2024
pulisher
Oct 04, 2024

Affimed N : Presentation - Marketscreener.com

Oct 04, 2024
pulisher
Oct 03, 2024

Analysts Set Affimed (NASDAQ:AFMD) Target Price at $20.00 - MarketBeat

Oct 03, 2024
pulisher
Sep 30, 2024

Affimed Appoints New CEO, Shares Fall on Leadership Change - MSN

Sep 30, 2024
pulisher
Sep 21, 2024

Affimed appoints Shawn Leland as chief executive officer - MSN

Sep 21, 2024
pulisher
Sep 17, 2024

Affimed (NASDAQ:AFMD) Sees Significant Decrease in Short Interest - MarketBeat

Sep 17, 2024
pulisher
Sep 13, 2024

AFMDAffimed N.V. Latest Stock News & Market Updates - StockTitan

Sep 13, 2024
pulisher
Sep 12, 2024

Affimed N.V. Announces Upcoming EGM - TipRanks

Sep 12, 2024
pulisher
Sep 10, 2024

Affimed to Present at the Cantor Global Healthcare Conference 2024 - GlobeNewswire

Sep 10, 2024
pulisher
Sep 10, 2024

Affimed (NASDAQ:AFMD) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World

Sep 10, 2024
pulisher
Sep 08, 2024

Affimed (NASDAQ:AFMD) Receives Consensus Rating of "Buy" from Analysts - MarketBeat

Sep 08, 2024
pulisher
Sep 07, 2024

Affimed N.V. (NASDAQ:AFMD) Q2 2024 Earnings Call Transcript - Insider Monkey

Sep 07, 2024
pulisher
Sep 06, 2024

HC Wainwright Reaffirms Buy Rating for Affimed (NASDAQ:AFMD) - MarketBeat

Sep 06, 2024
pulisher
Sep 06, 2024

Earnings call: Affimed reports promising clinical results and stable finances By Investing.com - Investing.com Australia

Sep 06, 2024
pulisher
Sep 06, 2024

Earnings call: Affimed reports promising clinical results and stable finances - Investing.com

Sep 06, 2024
pulisher
Sep 06, 2024

Affimed NV (AFMD) Q2 2024 Earnings Call Transcript Highlights: F - GuruFocus.com

Sep 06, 2024
pulisher
Sep 06, 2024

Affimed N.V.: Q2 Earnings Snapshot - New Haven Register

Sep 06, 2024

Affimed N V Stock (AFMD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):